Voya Investment Management LLC Cuts Position in IQVIA Holdings Inc. $IQV

Voya Investment Management LLC cut its stake in IQVIA Holdings Inc. (NYSE:IQV) by 1.7% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 55,996 shares of the medical research company’s stock after selling 955 shares during the period. Voya Investment Management LLC’s holdings in IQVIA were worth $9,872,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Continuum Advisory LLC grew its stake in shares of IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company’s stock valued at $354,000 after buying an additional 64 shares during the last quarter. Ballentine Partners LLC grew its stake in shares of IQVIA by 4.9% during the first quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company’s stock valued at $260,000 after buying an additional 69 shares during the last quarter. Independent Advisor Alliance grew its stake in shares of IQVIA by 4.2% during the first quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company’s stock valued at $318,000 after buying an additional 72 shares during the last quarter. ST Germain D J Co. Inc. grew its stake in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares during the last quarter. Finally, Nemes Rush Group LLC grew its stake in shares of IQVIA by 15.0% during the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company’s stock valued at $109,000 after buying an additional 81 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of NYSE IQV opened at $186.97 on Wednesday. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $248.03. The company has a 50 day simple moving average of $183.32 and a two-hundred day simple moving average of $167.24. The company has a market capitalization of $31.78 billion, a price-to-earnings ratio of 27.06, a P/E/G ratio of 2.04 and a beta of 1.32. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The business had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. During the same quarter last year, the firm earned $2.64 earnings per share. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IQV. Redburn Partners set a $214.00 price objective on IQVIA in a research note on Wednesday, September 3rd. Cowen reaffirmed a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. UBS Group upped their price objective on shares of IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a research note on Wednesday, July 23rd. Barclays upped their price objective on shares of IQVIA from $165.00 to $185.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 23rd. Finally, Citigroup reaffirmed a “neutral” rating on shares of IQVIA in a research note on Thursday, May 22nd. Eighteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $229.64.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.